TapewireFind a company

person · Reporting owner

Vaddi Krishna

Disclosed activity across 1 company

Tapewire entity
67553
SEC CIK
0001824633

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Prelude Therapeutics IncPRLD · Entity 5561Director · CEOFebruary 04, 2026February 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Prelude Therapeutics Inc

Report date February 04, 2026 · Filed February 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2036-02-03Direct837,000 Reported balance After 2026-02-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-02-04 · Grant · Acquired 837,000 · Balance 837,000

F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 04, 2026 Filed Feb 5, 2026 21:10 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (right to buy) · Derivative 837,000 $0.00 Strike: $2.30 $0.00
Disclosure

SEC source: 0001824633-26-000002 · primarydocument.xml · derivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 837,000

Underlying: Common Stock · 837,000 shares

Expires 2036-02-03

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
March 25, 2025 Filed Mar 27, 2025 20:37 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 675,000 $0.69 $467,437.50
Disclosure

SEC source: 0001562180-25-002778 · primarydocument.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,999,296

Read SEC document
March 21, 2025 Filed Mar 24, 2025 21:03 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 15,000 $0.73 $10,959.00
Disclosure

SEC source: 0001562180-25-002697 · primarydocument.xml · nonDerivative · entry 2

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,324,296

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.73 to $0.731, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Read SEC document
March 20, 2025 Filed Mar 24, 2025 21:03 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 5,416 $0.73 $3,950.43
Disclosure

SEC source: 0001562180-25-002697 · primarydocument.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,309,296

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7294 to $0.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Read SEC document
March 17, 2025 Filed Mar 18, 2025 20:27 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 9,106 $0.75 $6,828.59
Disclosure

SEC source: 0001562180-25-002541 · primarydocument.xml · nonDerivative · entry 2

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,303,880

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7496 to $0.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 20:27 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 29,999 $0.75 $22,631.25
Disclosure

SEC source: 0001562180-25-002541 · primarydocument.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,294,774

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7746 to $0.7782, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Read SEC document
March 13, 2025 Filed Mar 14, 2025 12:02 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 50,000 $0.72 $35,820.00
Disclosure

SEC source: 0001562180-25-002392 · primarydocument.xml · nonDerivative · entry 2

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,264,775

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6993 to $0.7999, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Read SEC document
March 12, 2025 Filed Mar 14, 2025 12:02 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 47,500 $0.71 $33,744.00
Disclosure

SEC source: 0001562180-25-002392 · primarydocument.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,214,775

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.693 to $0.7512, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Read SEC document
February 04, 2025 Filed Feb 5, 2025 21:30 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (right to buy) · Derivative 496,000 $0.00 Strike: $1.11 $0.00
Disclosure

SEC source: 0001562180-25-000955 · primarydocument.xml · derivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 496,000

Underlying: Common Stock · 496,000 shares

Expires 2035-02-04

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
December 31, 2024 Filed Jan 3, 2025 12:41 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 5,000 $1.21 $6,043.50
Disclosure

SEC source: 0001562180-25-000031 · primarydocument.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 142,553

F1 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Read SEC document
December 30, 2024 Filed Jan 2, 2025 21:09 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 10,000 $1.20 $12,000.00
Disclosure

SEC source: 0001562180-25-000008 · primarydocument.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 137,553

F1 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Read SEC document
December 19, 2024 Filed Dec 20, 2024 12:33 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 6,888 $0.89 $6,115.86
Disclosure

SEC source: 0001562180-24-008531 · primarydocument.xml · nonDerivative · entry 2

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 127,553

F2 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Read SEC document
December 18, 2024 Filed Dec 20, 2024 12:33 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 100,000 $0.93 $93,210.00
Disclosure

SEC source: 0001562180-24-008531 · primarydocument.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,167,275

F1 · price: 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.89 to $1.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Read SEC document
March 01, 2024 Filed Mar 4, 2024 22:59 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (right to buy) · Derivative 425,000 $0.00 Strike: $4.59 $0.00
Disclosure

SEC source: 0001562180-24-002127 · primarydocument.xml · derivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 425,000

Underlying: Common Stock · 425,000 shares

Expires 2034-02-28

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
May 25, 2023 Filed May 26, 2023 20:20 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 900 $5.31 $4,779.00
Disclosure

SEC source: 0001562180-23-004517 · primarydocument.xml · nonDerivative · entry 2

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,067,275

F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.

Read SEC document
May 24, 2023 Filed May 26, 2023 20:20 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 1,000 $5.01 $5,011.40
Disclosure

SEC source: 0001562180-23-004517 · primarydocument.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,066,375

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.99 to $5.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.

Read SEC document
May 23, 2023 Filed May 25, 2023 20:03 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 11,856 $5.63 $66,749.28
Disclosure

SEC source: 0001562180-23-004474 · primarydocument.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,065,375

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.45 to $5.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 21:07 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (right to buy) · Derivative 330,000 $0.00 Strike: $7.20 $0.00
Disclosure

SEC source: 0001562180-23-001166 · primarydocument.xml · derivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,000

Underlying: Common Stock · 330,000 shares

Expires 2033-02-06

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
December 20, 2022 Filed Dec 21, 2022 21:08 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 19,188 $5.13 $98,445.95
Disclosure

SEC source: 0001562180-22-008404 · primarydocument.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 120,665

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Read SEC document
February 15, 2022 Filed Feb 18, 2022 00:09 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (right to buy) · Derivative 327,900 $0.00 Strike: $10.58 $0.00
Disclosure

SEC source: 0001209191-22-011035 · doc4.xml · derivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 327,900

Underlying: Common Stock · 327,900 shares

Expires 2032-02-14

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
December 13, 2021 Filed Dec 14, 2021 22:36 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantCommon Stock 8,000 $12.13 $97,035.20
Disclosure

SEC source: 0001209191-21-069547 · doc4.xml · nonDerivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,053,519

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.01 to $12.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.

Read SEC document
July 20, 2021 Filed Jul 22, 2021 22:16 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (Right to Buy) · Derivative 285,800 $0.00 Strike: $31.23 $0.00
Disclosure

SEC source: 0001209191-21-047845 · doc4.xml · derivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,800

Underlying: Common Stock · 285,800 shares

Expires 2031-07-19

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
September 29, 2020 Filed Sep 30, 2020 00:06 UTC Prelude Therapeutics Inc PRLD · Entity 5561 ConversionSeries A Preferred Stock · Derivative 32,876 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-052399 · doc4.xml · derivative · entry 8

Vaddi Krishna · CIK 0001824633 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 32,876 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F5 · ownership.nature: The Reporting Person is the investment advisor of the Brocade Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Read SEC document
September 29, 2020 Filed Sep 30, 2020 00:06 UTC Prelude Therapeutics Inc PRLD · Entity 5561 ConversionSeries A Preferred Stock · Derivative 32,876 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-052399 · doc4.xml · derivative · entry 7

Vaddi Krishna · CIK 0001824633 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 32,876 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F4 · ownership.nature: The Reporting Person is the investment advisor of the Blue Sky Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Read SEC document
September 29, 2020 Filed Sep 30, 2020 00:06 UTC Prelude Therapeutics Inc PRLD · Entity 5561 ConversionSeries A Preferred Stock · Derivative 101,477 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-052399 · doc4.xml · derivative · entry 6

Vaddi Krishna · CIK 0001824633 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 101,477 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F3 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Read SEC document
September 29, 2020 Filed Sep 30, 2020 00:06 UTC Prelude Therapeutics Inc PRLD · Entity 5561 ConversionCommon Stock 32,876 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-052399 · doc4.xml · nonDerivative · entry 4

Vaddi Krishna · CIK 0001824633 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 551,774

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F5 · ownership.nature: The Reporting Person is the investment advisor of the Brocade Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Read SEC document
September 29, 2020 Filed Sep 30, 2020 00:06 UTC Prelude Therapeutics Inc PRLD · Entity 5561 ConversionCommon Stock 32,876 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-052399 · doc4.xml · nonDerivative · entry 3

Vaddi Krishna · CIK 0001824633 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 551,776

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F4 · ownership.nature: The Reporting Person is the investment advisor of the Blue Sky Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Read SEC document
September 29, 2020 Filed Sep 30, 2020 00:06 UTC Prelude Therapeutics Inc PRLD · Entity 5561 ConversionCommon Stock 101,477 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-052399 · doc4.xml · nonDerivative · entry 2

Vaddi Krishna · CIK 0001824633 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 101,477

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.

F3 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.